Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CV Therapeutics Inc.

Division of Gilead Sciences Inc.

Latest From CV Therapeutics Inc.

Deal Watch: Teva's Sol Barer Leads Buyout Of IO Start-up NexImmune

Instead of helping raise a Series A, the Teva chairman and others acquire the preclinical company, convinced of its synthetic nanotech promise in immuno-oncology. Vifor and ChemoCentryx expand their orphan and renal disease collaboration, while Gilead out-licenses an addiction drug candidate.

Commercial Deals

Has Aldea Hit On A Sober Approach To Alcohol-Intoxication Therapy?

Acute alcohol intoxication is an unmet medical need that can be both lethal and a cost drain for the health care system, Aldea says. It plans to develop its lead candidate, an ALDH-2 activator, for the rare genetic disorder Fanconi anemia as well.

BioPharmaceutical United States

FDA tightens warnings for Astellas stress agents but generics a bigger threat?

Two cardiac stress test agents marketed in the US by Astellas Pharma are the subject of a new warning from the FDA over a "rare but serious risk of heart attack and death" in certain patients, prompted by recent reports of serious adverse events.


FDA Seeks Alternatives To QT Interval For Assessing Risk Of Torsade de Pointes

A clinical study funded by the Critical Path Initiative is looking at the change in a number of electrocardiogram parameters in patients given drugs known to prolong the QT interval and with varying risks for the abnormal heart rhythm.

BioPharmaceutical North America
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Gilead Sciences Inc.
  • Senior Management
  • Louis G Lange, MD, PhD, Chmn. & CEO
    Daniel K Spiegelman, SVP, CFO
    Brent K Blackburn, PhD, SVP, Drug Discovery & Dev.
    John Mohr, SVP, Bus. Dev.
  • Contact Info
  • CV Therapeutics Inc.
    Phone: (650) 384-8500
    3172 Porter Dr.
    Palo Alto, CA 94304